ArticleTherapeutic advances in drug safety2026
Adverse events associated with statin co-use in breast cancer patients: a disproportionality analysis based on the FDA Adverse Event Reporting System.
Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: An increasing number of breast cancer patients are using statins concomitantly. However, there are relatively few safety studies on the association between statins and adverse events (AEs) during breast cancer treatment. Objective: This study aims to systematically evaluate the disproportionality signals associated with statin use and the reporting of AEs across different system organ classes (SOCs) in breast cancer patients. Design: This is a pharmacovigilance disproportionality analysis based on the U.S. Food and Drug Administration's (FDA) Adverse Event Reporting System database. Methods: All AE reports related to breast cancer from the 2004 Q1 to 2024 Q3 were extracted. Disproportionality analysis was performed using reporting odds ratios (RORs) to detect potential safety signals associated with statin use. Multivariate logistic regression model was used as a secondary analysis to adjust for potential confounders, including age, gender, and therapeutic drugs. Results: A total of 237,868 breast cancer-related AE reports were identified, of which 8,223 involved concomitant statin use. Statin use was associated with lower RORs of hepatobiliary (ROR: 0.60, 95% CI: 0.52-0.68), and blood and lymphatic system disorders (ROR: 0.62, 95% CI: 0.57-0.67). In contrast, higher RORs were observed for skin and subcutaneous tissue (ROR: 1.75, 95% CI: 1.67-1.84), psychiatric (ROR: 1.95, 95% CI: 1.82-2.08), renal and urinary (ROR: 2.03, 95% CI: 1.85-2.22), musculoskeletal and connective tissue (ROR: 1.48, 95% CI: 1.40-1.58), infections and infestations (ROR: 1.25, 95% CI: 1.18-1.34), metabolism and nutrition (ROR: 1.25, 95% CI: 1.16-1.35), gastrointestinal (ROR: 1.10, 95% CI: 1.05-1.16), vascular (ROR: 1.26, 95% CI: 1.16-1.37), nervous system (ROR: 1.20, 95% CI: 1.13-1.27), respiratory, thoracic and mediastinal disorders (ROR: 1.07, 95% CI: 1.00-1.14). Conclusion: In breast cancer patients receiving statins concomitantly, specific disproportionality signals were observed across multiple SOCs. These findings highlight the need for individualized monitoring strategies and further mechanistic studies to clarify the underlying pathways and optimize clinical risk management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.